Clinical biochemistry
-
Clinical biochemistry · Jun 2013
Limited clinical value of multiple blood markers in the diagnosis of ischemic stroke.
No ideal blood marker exists for the diagnosis of ischemic stroke. Combined use of multiple blood markers would enhance the ability of clinical diagnosis of ischemic stroke. ⋯ IL-6, S100B, and MMP-9 markers are elevated in the peripheral blood during the acute phase of ischemic stroke. However, the clinical usefulness of these biomarkers is limited due to low discriminating ability when compared to clinical parameters alone in diagnosis of ischemic stroke.
-
Clinical biochemistry · May 2013
Randomized Controlled TrialPrevention of hemolysis in blood samples collected from intravenous catheters.
Samples drawn through intravenous catheters are frequently hemolyzed. We planned a prospective, randomized study to establish whether hemolysis in samples drawn from intravenous catheters may be reduced using S-Monovette® tubes collected by manual aspiration as compared with standard vacuum tubes. ⋯ S-Monovette can be used with vacuum or aspiration collection. This latter approach allows blood drawing with limited shear stress and less likelihood of generating spuriously hemolysis.
-
Clinical biochemistry · Feb 2013
Comparative StudyDiagnostic accuracy of soluble urokinase plasminogen activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndrome.
Soluble urokinase plasminogen activator receptor (suPAR) serum concentrations have recently been described to reflect the severity status of systemic inflammation. In this study, the diagnostic accuracy of suPAR, C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6) to predict bacteremia in patients with systemic inflammatory response syndrome (SIRS) was compared. ⋯ In conclusion, suPAR, IL-6 and PCT may contribute to predicting bacteremia in SIRS patients.
-
Clinical biochemistry · Jan 2013
Predicting myocardial infarction and other serious cardiac outcomes using high-sensitivity cardiac troponin T in a high-risk stable population.
Previous work on high-sensitivity troponin I (hs-cTnI) has demonstrated that it may identify patients with stable cardiovascular disease (CVD) at risk for future myocardial infarction (MI). In this study, we assessed if hs-cTnT concentrations could also identify those stable CVD patients at high risk for future MI and other ischemic cardiac outcomes. ⋯ In patients with stable CVD disease hs-cTnT measurement identifies those at risk for MI as well as HF and cardiovascular death.